Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations
After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.
After the United States Preventative Services Task Force (USPSTF) recommended against all men being screened for prostate cancer, there was a decrease in the incidence around the nation, according to MaryBeth Freeman, MPH, senior associate scientist at the American Cancer Society.
Freeman also emphasized that the USPSTF updated their guidelines again in 2018 to state that men should have thorough discussions with their healthcare providers about the risks and benefits of prostate cancer screening, as it pertains to them individually. This will prevent over-screening in this population, while also ensuring that men who may be at risk for the disease are still getting the appropriate screening and potential diagnosis.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
